Neoplasms Clinical Trial
— PICOfficial title:
Intérêt de la corticothérapie Dans la Pneumocystose Grave du Patient immunodéprimé Non VIH. Essai Prospectif Multicentrique Randomisé Contrôlé : PIC
Pneumocystis jiroveci pneumonia (PcP) increased in non HIV immunocompromised patients.
Mortality remains high for those patients with comorbidities (50% for patients with the most
severe Pneumocystis pneumonia). Physiopathology, characteristics and outcome of PcP in
non-HIV patients remains different from those in HIV patients. Steroids in HIV patients with
PcP has been associated with decreased mortality but in non-HIV patients, adjunctive steroids
remains controversy. Some retrospective studies in that field did not find any beneficial
effects of steroids ((1mg/kg/jour d'Equivalent Prednisone (EP)). However, all the studies
were retrospective, non randomised studies including various underlying disease and severity
of PcP was variable. Moreover, dosage and delay of steroids were variable leading difficult
to interpret all the results.
The investigators want to demonstrate the beneficial effect of steroid during PcP in non-HiV
immunocompromised patients with a double blinded randomised clinical trials comparing
adjunctive steroids to placebo.
Status | Recruiting |
Enrollment | 222 |
Est. completion date | October 2022 |
Est. primary completion date | October 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age = 18 years - Severe PcP : 1 / interstitial acute pneumonia with possible or typical criteria for PcP and positive specimen for Pneumocystis jirovecii (excluding PCR) ; or interstitial acute pneumonia with typical criteria for PcP and positive PCR in respiratory specimen. 2/ Arterial pression of Oxygen (PaO2) < 60 mmHg on room air need of 3 L/min oxygen for saturation >92% or tachypnea>30min need of mechanical ventilation for acute respiratory failure. - Treatment for PcP started for less than 7 days. - Non-HIV immunosuppression : malignant hematological disease, solid tumor cured for less than 5 years, allogenic stem cell transplant, Steroids (>0.3mg/kg equivalent prednisone for more than 3 weeks or > 20mg/days for more than one months) or other immunosuppressive treatment for more than one months or solid organ transplantation. - Signed inform consent by patient or relatives - Health insurance Exclusion Criteria: - HIV Serology HIV 1 or 2 positive - Need of steroid =1mg/kg/j equivalent prednisone for another pathology (acute Graft versus Host disease (GVH= for example) - Contra-indication for steroids - Pregnancy of breath-feeding - Denied to participate - No health insurance - tutelage |
Country | Name | City | State |
---|---|---|---|
France | Medical ICU | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mortality | 28 days mortality after the randomisation | Day 28 | |
Secondary | Mortality | 90 days mortality after the randomisation | Day 90 | |
Secondary | Hospital mortality | Mortality at hospital discharge | Day 120 | |
Secondary | ICU mortality | For patients admitted to ICU at ICU discharge | Day 90 | |
Secondary | Acute respiratory failure | Acute respiratory failure during treatment defined by one of those criteria within 28 days : Increased need of oxygen (more than 9 l/min of high flow nasal oxygen with Inspired Fraction of Oxygen (fiO2) >50%) Admission to ICU after randomisation Need of mechanical ventilation (invasive or non invasive) or high flow nasal oxygen |
Day 28 | |
Secondary | Duration of mechanical ventilation | Duration of mechanical ventilation invasive and/or non invasive | Day 28 | |
Secondary | Occurrence of septic shock | septic shock is defined as need for vasopressor | Day 28 | |
Secondary | acute kidney injury | KDIGO score >=1 | Day 28 | |
Secondary | Hospital acquired infectious disease | Global incidence incidence of infections. Incidence of pulmonary or extra-pulmonary infections. Incidence of bacterial, viral and fungal infections. Diagnosis of infectious disease will be defined by the need of treatment. |
Day 28 | |
Secondary | Hospital length of stay | Hospital length of stay at hospital discharge | Day 120 | |
Secondary | ICU length of stay | ICU length of stay at ICU discharge | Day 90 | |
Secondary | Duration of Insulin treatment | Insulin treatment is defined : patient without insulin treatment before study : start of insulin therapy patient treated with insulin before study : increased dose (>30%) of insulin |
Day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A |